Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ATROPINE AND DEMEROL vs ZEPATIER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Atropine is an antimuscarinic agent that competitively blocks acetylcholine at muscarinic receptors, reducing secretions and gastrointestinal motility. Meperidine (Demerol) is an opioid agonist that binds to mu-opioid receptors in the CNS, altering pain perception and producing analgesia.
ZEPATIER is a fixed-dose combination of elbasvir, an HCV NS5A inhibitor, and grazoprevir, an HCV NS3/4A protease inhibitor. Elbasvir inhibits HCV NS5A, disrupting viral replication and assembly. Grazoprevir inhibits the HCV NS3/4A serine protease, preventing cleavage of the HCV polyprotein into mature viral proteins.
Preanesthetic medication to reduce secretions and prevent bradycardia,Management of moderate to severe pain (as an opioid analgesic),Off-label: treatment of opioid-induced constipation (meperidine component)
Treatment of chronic hepatitis C virus (HCV) genotype 1 or 4 infection in adults,Treatment of chronic HCV genotype 1 or 4 infection in pediatric patients 12 years of age and older or weighing at least 30 kg
Atropine 0.4 mg and Demerol (meperidine) 50-100 mg intramuscularly as preanesthetic medication 30-60 minutes before procedure.
One tablet (elbasvir 50 mg/grazoprevir 100 mg) orally once daily.
Atropine: 2-4 hours (terminal half-life). Demerol: 2.5-4 hours; normeperidine metabolite half-life 15-30 hours (accumulates in renal impairment).
Elbasvir: terminal half-life approximately 24 hours. Grazoprevir: terminal half-life approximately 31 hours. The prolonged half-lives support once-daily dosing and allow for sustained viral suppression.
Meperidine is primarily metabolized in the liver via hydrolysis to meperidinic acid and via N-demethylation to normeperidine (active metabolite), involving CYP3A4 and CYP2B6. Atropine is metabolized in the liver via hydrolysis and glucuronidation; approximately 50% is excreted unchanged in urine.
Elbasvir is metabolized primarily by CYP3A. Grazoprevir is metabolized primarily by CYP3A. Mild oxidation and glucuronidation are minor pathways.
Atropine: approximately 50% excreted unchanged in urine, remainder as metabolites (biliary and renal). Demerol (meperidine): primarily hepatic metabolism; <5% excreted unchanged in urine; metabolites (including normeperidine) excreted renally.
Elbasvir: primarily biliary/fecal (≥90% as metabolites, <1% unchanged in urine). Grazoprevir: primarily biliary/fecal (≥90% as metabolites, <1% unchanged in urine). Renal elimination is negligible for both.
Atropine: ~44% bound to albumin and alpha-1 acid glycoprotein. Demerol: ~60% bound to albumin and alpha-1 acid glycoprotein.
Elbasvir: ≥99.9% bound, primarily to albumin and α1-acid glycoprotein. Grazoprevir: 98.8% bound, primarily to albumin and α1-acid glycoprotein.
Atropine: 1-3 L/kg (large, extensive tissue distribution). Demerol: 3-5 L/kg (large, distributes widely including CNS).
Elbasvir: apparent Vd approximately 4.5 L/kg (high, indicating extensive tissue distribution). Grazoprevir: apparent Vd approximately 19 L/kg (very high, likely due to binding to plasma proteins and tissue uptake).
Atropine: oral ~10-25% (extensive first-pass metabolism). Demerol: oral ~50-60% (significant first-pass metabolism). IM/IV 100%.
Elbasvir: absolute bioavailability not determined in humans; oral absorption is high. Grazoprevir: absolute bioavailability approximately 27% after oral administration; absorption is enhanced with food (high-fat meal increases AUC by 1.5-fold).
Meperidine: GFR 10-50 m L/min: administer 75% of normal dose; GFR <10 m L/min: administer 50% of normal dose and avoid due to normeperidine accumulation. Atropine: no adjustment required.
No dose adjustment required for any degree of renal impairment including end-stage renal disease on dialysis.
Meperidine: Child-Pugh A: reduce dose by 25%; Child-Pugh B: reduce by 50%; Child-Pugh C: contraindicated. Atropine: caution in severe hepatic impairment.
Contraindicated in moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment. No dose adjustment required in mild (Child-Pugh A) hepatic impairment.
Atropine 0.01 mg/kg (max 0.4 mg) and meperidine 1-2 mg/kg (max 100 mg) intramuscularly 30-60 minutes before procedure.
Not approved for use in pediatric patients; safety and efficacy not established.
Reduce meperidine dose by 50% and avoid in elderly due to risk of seizures and delirium; use alternative opioids. Atropine dose unchanged but monitor for anticholinergic effects.
No dose adjustment required; however, clinical studies indicate similar safety and efficacy as in younger adults, but caution is warranted due to potential age-related comorbidities.
Meperidine has a boxed warning for risk of respiratory depression, especially in elderly, cachectic, or debilitated patients, and when used with CNS depressants. Also, risk of serotonin syndrome when co-administered with serotonergic drugs, and risk of abuse, addiction, and diversion.
Risk of hepatitis B virus (HBV) reactivation in patients coinfected with HCV and HBV, which may result in fulminant hepatitis, hepatic failure, and death. Test all patients for evidence of current or prior HBV infection before initiating treatment.
Respiratory depression, hypotension, bradycardia, urinary retention, constipation, serotonin syndrome, seizures (normeperidine accumulation), decreased GI motility, drug dependence, and tolerance. Use caution in elderly, renal impairment, hepatic impairment, respiratory disorders, prostatic hyperplasia, glaucoma, and with concurrent CNS depressants.
Risk of hepatitis B virus reactivation,Hepatic decompensation with use in patients with moderate or severe hepatic impairment (Child-Pugh B or C),Elevation of total bilirubin and/or ALT levels,Risk of adverse reactions due to drug interactions (e.g., strong CYP3A inducers/inhibitors)
Hypersensitivity to atropine or meperidine; severe asthma or COPD; acute respiratory depression; paralytic ileus; known or suspected gastrointestinal obstruction; patients receiving MAOIs (within 14 days); myasthenia gravis (relative for atropine); increased intraocular pressure (glaucoma); severe renal impairment (normeperidine accumulation).
Moderate or severe hepatic impairment (Child-Pugh B or C),Use with strong CYP3A inducers (e.g., rifampin, St. John's wort, carbamazepine, phenytoin),Use with certain HIV medications (e.g., efavirenz, etravirine, nevirapine, atazanavir/ritonavir, lopinavir/ritonavir, darunavir/ritonavir, tipranavir/ritonavir),Use with cyclosporine
Avoid alcohol. Meperidine may interact with foods containing tyramine (aged cheeses, cured meats) in patients on MAOIs; otherwise no significant food interactions.
ZEPATIER can be taken with or without food. No specific food restrictions are required. Grapefruit and grapefruit juice may increase exposure to grazoprevir; although not contraindicated, consider avoiding large quantities.
Atropine: FDA Pregnancy Category C. Crosses placenta; may cause fetal tachycardia. Demerol (meperidine): FDA Pregnancy Category C. First trimester: limited human data; animal studies show no teratogenicity. Second trimester: no specific risks. Third trimester: use near term may cause neonatal respiratory depression, decreased Apgar scores, and withdrawal symptoms. Chronic use may lead to neonatal opioid withdrawal syndrome (NOWS).
ZEPATIER (grazoprevir/elbasvir) is contraindicated in pregnancy due to the ribavirin component in some regimens. Ribavirin is teratogenic in all trimesters, causing fetal malformations and embryolethality. Grazoprevir/elbasvir alone has no adequate human data, but animal studies show no teratogenicity. However, combination with ribavirin mandates avoidance in pregnancy.
Atropine: Excreted in breast milk in small amounts; may inhibit lactation. M/P ratio not established. Use with caution; monitor infant for anticholinergic effects (tachycardia, dry mouth). Demerol: Excreted in breast milk; relative infant dose (RID) ~0.5-0.8% of maternal weight-adjusted dose. M/P ratio 1.0-1.6. Limited data; avoid in breastfeeding due to potential neonatal sedation and respiratory depression. American Academy of Pediatrics considers meperidine compatible but caution advised.
No data on human milk excretion. M/P ratio unknown. Ribavirin accumulates in breast milk and is contraindicated during breastfeeding. Grazoprevir/elbasvir: animal studies show excretion in milk; potential for adverse effects. Avoid breastfeeding during treatment and for 7 days after last dose.
Atropine: No specific dose adjustments recommended; increased volume of distribution may require higher doses for effect. Demerol: Increased clearance and volume of distribution in pregnancy; standard doses may be less effective. Avoid use during labor due to risk of neonatal respiratory depression; if necessary, use lowest effective dose and monitor neonate. No specific dose reduction recommended, but caution with repeated doses.
No dose adjustment studies in pregnancy. ZEPATIER is not recommended during pregnancy due to ribavirin component. If inadvertently used, no specific dose adjustment; consult maternal-fetal specialist.
Atropine and Demerol (meperidine) combination is used for pre-anesthetic medication to reduce secretions and produce sedation. Monitor for CNS depression, respiratory depression, and anticholinergic effects (tachycardia, dry mouth, urinary retention). Use cautiously in elderly, patients with COPD, asthma, or prostatic hyperplasia. Avoid in patients with MAOIs due to risk of serotonin syndrome.
ZEPATIER (elbasvir/grazoprevir) is indicated for chronic HCV genotypes 1 or 4. Prior to initiation, test for NS5A resistance-associated substitutions (RASs) in genotype 1a. In patients with genotype 1a and baseline NS5A RASs, treatment duration is 16 weeks with ribavirin. Avoid in moderate to severe hepatic impairment (Child-Pugh B or C). Monitor hepatic function closely. Coadministration with strong CYP3A4 inducers (e.g., rifampin, carbamazepine) is contraindicated. Also contraindicated with OATP1B1/3 inhibitors (e.g., cyclosporine) and certain HIV protease inhibitors (e.g., atazanavir, darunavir, lopinavir). Grazoprevir increases serum creatinine due to OATP2B1 inhibition, but this does not reflect true renal function decline.
This medication may cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until effects are known.,Avoid alcohol and other CNS depressants while taking this medication.,Report difficulty urinating, fast heartbeat, or severe constipation to your healthcare provider.,Do not take more than prescribed; risk of dependence with long-term use.,Keep out of reach of children; may cause serious breathing problems if accidentally taken.
Take ZEPATIER exactly as prescribed, one tablet once daily with or without food.,Do not stop or skip doses without consulting your healthcare provider.,Inform your doctor of all medications you take, including over-the-counter drugs and herbal supplements, to avoid serious interactions.,Notify your healthcare provider immediately if you experience symptoms of liver problems: yellowing of skin or eyes, dark urine, pale stools, nausea, vomiting, or right upper abdominal pain.,ZEPATIER may elevate creatinine levels without reflecting kidney damage; your doctor will monitor appropriately.,If you have genotype 1a HCV, your doctor will test for specific resistance mutations to determine the correct treatment duration.,Avoid alcohol during treatment as it can exacerbate liver injury.,Use effective contraception during treatment and for 2 weeks after the last dose if you or your partner can become pregnant.
"Rivastigmine, a reversible carbamate acetylcholinesterase inhibitor, increases synaptic acetylcholine levels, enhancing cholinergic transmission. Atropine, a competitive antagonist of muscarinic acetylcholine receptors, blocks the effects of acetylcholine at these receptors, leading to reduced parasympathetic activity. When used together, atropine can diminish the therapeutic efficacy of rivastigmine by pharmacodynamically antagonizing its cholinergic effects, particularly in the central nervous system and peripheral muscarinic receptors, potentially worsening cognitive function in Alzheimer's disease patients."
"Umeclidinium, a long-acting muscarinic antagonist (LAMA), and atropine, a non-selective muscarinic antagonist, both block the action of acetylcholine at muscarinic receptors in the parasympathetic nervous system. Their co-administration leads to additive anticholinergic effects, resulting in an increased risk of peripheral anticholinergic adverse effects such as dry mouth, blurred vision, constipation, urinary retention, and tachycardia, as well as central nervous system effects like confusion or delirium, especially in elderly patients. Clinically, this combination may also exacerbate conditions such as angle-closure glaucoma or paralytic ileus."
"Concurrent use of atropine and gallamine triethiodide results in additive antagonism at muscarinic acetylcholine receptors, leading to enhanced blockade of parasympathetic effects and increased risk of tachycardia, hypertension, and delirium. Atropine, a competitive antagonist of muscarinic receptors, counteracts the vagolytic effects of gallamine, a nondepolarizing neuromuscular blocker that also exhibits weak vagolytic activity. This pharmacodynamic interaction can cause severe sinus tachycardia, hypertension, and central anticholinergic syndrome, especially in elderly patients or those with cardiovascular disease."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ATROPINE AND DEMEROL vs ZEPATIER, answered by our medical review team.
ATROPINE AND DEMEROL is a Opioid Analgesic Combination that works by Atropine is an antimuscarinic agent that competitively blocks acetylcholine at muscarinic receptors, reducing secretions and gastrointestinal motility. Meperidine (Demerol) is an opioid agonist that binds to mu-opioid receptors in the CNS, altering pain perception and producing analgesia.. ZEPATIER is a Direct-Acting Antiviral (HCV) that works by ZEPATIER is a fixed-dose combination of elbasvir, an HCV NS5A inhibitor, and grazoprevir, an HCV NS3/4A protease inhibitor. Elbasvir inhibits HCV NS5A, disrupting viral replication and assembly. Grazoprevir inhibits the HCV NS3/4A serine protease, preventing cleavage of the HCV polyprotein into mature viral proteins.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ATROPINE AND DEMEROL and ZEPATIER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ATROPINE AND DEMEROL is: Atropine 0.4 mg and Demerol (meperidine) 50-100 mg intramuscularly as preanesthetic medication 30-60 minutes before procedure.. The standard adult dose of ZEPATIER is: One tablet (elbasvir 50 mg/grazoprevir 100 mg) orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ATROPINE AND DEMEROL and ZEPATIER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ATROPINE AND DEMEROL is classified as Category C. Atropine: FDA Pregnancy Category C. Crosses placenta; may cause fetal tachycardia. Demerol (meperidine): FDA Pregnancy Category C. First trimester: limited human data; animal studi. ZEPATIER is classified as Category C. ZEPATIER (grazoprevir/elbasvir) is contraindicated in pregnancy due to the ribavirin component in some regimens. Ribavirin is teratogenic in all trimesters, causing fetal malformat. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.